Discover more from Courageous Discourse™ with Dr. Peter McCullough & John Leake
Anti-Spike Antibodies are Associated with Long-COVID-19 Syndrome
Aberrant Antibodies Higher in Vaccinated after COVID-19--Explains Post-Acute Sequelae
By Peter A. McCullough, MD, MPH
With the deluge of post-COVID syndrome patients, doctors have been searching for diagnostic tests which can aid in detection, management, and prognosis. Additionally, those who took one of the COVID-19 vaccines appear to have worsened symptoms, and therefore, it makes sense they may have some clues on lab testing.
The principle mechanism of action of mRNA or adenoviral DNA COVID-19 vaccination is to stimulate the production of anti-Spike antibodies. Here is what Labcorp says about this test: “On May 19, 2021, the FDA issued a safety communication reiterating that “antibody testing should not be used to evaluate a person’s level of immunity or protection from COVID-19 at any time, and especially after the person received a COVID-19 vaccination.” Currently authorized SARS-CoV-2 antibody tests, including the SARS-CoV-2 Semi-Quantitative Total Antibody assay, have not been evaluated to assess the level of protection provided by an immune response to COVID-19 vaccination. Additionally, the components of a protective immune response against infection or re-infection with SARS-CoV-2 have not been fully characterized (e.g., antibody, T cell, etc.). Clinical trials and other studies are underway to elucidate the correlates of immunity to SARS-CoV-2.
Effective March 28, 2022 Labcorp expanded the reporting range of results for test number SARS-CoV-2 Semi-Quantitative Total Antibody, Spike. Results previously reported for this assay were 0.8-2,500 U/mL with higher values reported as >2,500 U/mL. With the addition of an automated dilution, we are now able to report result 0.8-25,000 U/mL with higher values reported as >25,000 U/mL. This change does not impact previously reported results; it just increases the numerical values above 2,500 U/mL that we are able to report.”
Joung et al, found that anti-spike antibody levels were higher for vaccinated compared to unvaccinated patients and the absolute level was associated with post-acute sequalae or long-COVID-19 syndrome. They postulate that the vaccine may cause aberrant antibodies that do not stop SARS-CoV-2 but rather negatively interact with the ACE-2 receptor which is ubiquitous in the body.
IgG antibodies against the Spike protein may be associated with post-COVID/vaccine syndromes while antibodies (acute IgM, convalescent IgG) directed against the nucleocapsid and T-cell immunity may be protective against the prolonged syndrome(s). I have noticed in my practice that anti-Spike antibody levels are associated with the duration and severity of long-COVID-19 and vaccine injury syndromes. While the antibodies should have never been used as clinical surrogates to approve or extend EUA applications for vaccines (as the LabCorp disclaimer indicates), they are useful in identifying the frequent complications after the unwise injections.
If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.
Joung S, Weber B, Wu M, Liu Y, Tang AB, Driver M, Sternbach S, Wynter T, Hoang A, Barajas D, Kao YH, Khuu B, Bravo M, Masoom H, Tran T, Sun N, Botting PG, Claggett BL, Prostko JC, Frias EC, Stewart JL, Robertson J, Kwan AC, Torossian M, Pedraza I, Sterling C, Goldzweig C, Oft J, Zabner R, Fert-Bober J, Ebinger JE, Sobhani K, Cheng S, Le CN. Serological response to vaccination in post-acute sequelae of COVID. BMC Infect Dis. 2023 Feb 16;23(1):97. doi: 10.1186/s12879-023-08060-y. PMID: 36797666; PMCID: PMC9933819.